In Europe, antibiotic resistance results in excess mortality, hospital stays and hospital expenditure, report results published in PLoS Medicine.
The researchers combined prospective data on the burden of methicillin-resistant Staphylococcus aureus
(MRSA) and third-generation cephalosporin-resistant Escherichia coli
bloodstream infections with 2007 prevalence data from the European Antibiotic Resistance Surveillance System (EARSS) to calculate excess mortality, excess hospital stay, and hospital expenditure. Data from 1293 hospitals in 31 countries revealed that an estimated 5,503 excess deaths were associated with bloodstream infections caused by MRSA (with the UK and France predicted to experience the highest excess mortality) and 2,712 excess deaths from bloodstream infections caused by third-generation cephalosporin-resistant E. coli
(predicted to be the highest in Turkey and the UK). The researchers also found that bloodstream infections caused by MRSA and third-generation cephalosporin-resistant E. coli
contributed an excess of 255,683 and 120,065 extra bed-days respectively. This translated to an estimated extra cost of 62.0 million Euros (92.8 million international dollars) attributable to these infections.
By looking at trends in their analyses they also estimate that 97,000 resistant bloodstream infections and 17,000 associated deaths could occur in 2015, with associated increases in hospital stay and costs. They finish by saying that 'Forecasts about changes in the coming years are disturbing; despite anticipated gains in the control of MRSA, the persistently increasing number of infections caused by third-generation cephalosporin-resistant Gram-negative pathogens is likely to outweigh this achievement soon.'